Tempest Therapeutics president Tom Dubensky resigns; CEO Stephen Brady to assume president role

Tempest Therapeutics, Inc.

Tom Dubensky resigned as president and board member effective Sep 2, 2023; will transition to advisor role on Sep 15, 2023.
Resignation not due to any disagreement with Tempest on operations, policies, or practices.
CEO Stephen Brady will be appointed as president and CEO effective Sep 15, 2023; his responsibilities unchanged.
Dubensky expected to enter consulting agreement: $8,000 retainer for initial period (Sep 15–Oct 15), then $500/hour for services.
Consulting period expected until at least Dec 15, 2023.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Stephen Brady

President and Chief Executive Officer

TPST · Tempest Therapeutics, Inc.

Effective: 2023-09-15
Filed: September 7, 2023, 7:59 PM ET

the Board will appoint Stephen Brady, the Company’s chief executive officer, as president and chief executive officer effective as of the Separation Date

Departed

Tom Dubensky

President and member of the Board of Directors

TPST · Tempest Therapeutics, Inc.

Effective: 2023-09-02
Successor: Stephen Brady
Filed: September 7, 2023, 7:59 PM ET

On September 2, 2023, Tom Dubensky, Ph.D. resigned from his role as president and member of the Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Stephen Brady was appointed as President and Chief Executive Officer at Tempest Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Board will appoint Stephen Brady, the Company’s chief executive officer, as president and chief executive officer effective as of the Separation Date

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Tom Dubensky resigned as President and member of the Board of Directors at Tempest Therapeutics, Inc..

Action: resigned
Role: President and member of the Board of Directors

Exact text from the filing

On September 2, 2023, Tom Dubensky, Ph.D. resigned from his role as president and member of the Board of Directors

View on SEC.gov

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-230659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.